In ovarian cancer, increased levels of EGF stimulate IL6 secretion, which promote the mobility and resistance to chemotherapy via the JAK/STAT3, SHP-2/Ras, MAPK, and PI3K/Akt signaling pathways [111, 113]. Here, STAT3 is linked to ovarian carcinoma.